PUBLIC PORTAL

MEDICALLY REVIEWED

Singapore’s HSA approves vericiguat (Verquvo) for use in high-risk heart failure patients with reduced ejection fraction

Share on email
Share on print
Share on whatsapp

Background
Heart failure (HF) is a significant health problem with a prevalence of 4.5% in Singapore, and over 26 million globally. More than half of HF patients . . .

Login or Sign Up as a healthcare professional to read the full article.

Share via

Share on email
Share on facebook
Share on whatsapp
Share on telegram
Share on twitter
Share on linkedin

Also worth reading